Bisphosphonates may reduce risk of certain breast, colon, and lung cancers
the ONA take:
According to two new studies published in the journal Proceedings of the National Academy of Sciences (PNAS), researchers at the Icahn School of Medicine at Mount Sinai in New York, New York, have found that bisposphonates, a commonly used class of drug to treat osteoporosis, may also prevent certain types of breast, colon, and lung cancers.
The first study analyzes how bisphosphonates block abnormal tumor growth through the human epidermal growth factor (HER) receptors, and the second study describes how bisphosphonates could be used in cancer prevention, in combination with existing treatments, and against treatment-resistant cancers. Certain types of breast, colon, and non-small cell lung cancers are driven by genetic mutations that cause the overexpression of HER family receptors.
The study found that bisphosphonates bind to kinase domains for HER proteins, thereby preventing pathway signaling that would ultimately cause cancer growth. This mechanism is similar to that of drugs that inhibit tyrosine kinases like trastuzumab and erlotinib; however, cancers often become resistant to these treatments after the tumor develops a second genetic mutation.
The findings suggest that bisphosphonates may continue to inhibit HER family receptors even after a second mutation is present, making these drugs a potential treatment for those cancers that become resistant to primary therapy.
Bisposphonates may also prevent certain types of breast, colon, and lung cancers.
- Ixazomib, a New PI, Offers Improved Efficacy With Acceptable Toxicity Profile for Relapsed/Refractory Multiple Myeloma
- Acupuncture May Improve Fatigue in Patients with Lung Cancer
- "Light" Cigarettes and Cancer Risk (Fact Sheet)
- A Review of CDK4/6 Toxicities and Interactions Management in Breast Cancer
- Vitamin D3 Supplementation Has No Impact on Breast Density Percentage, Breast Cancer Risk
- Dexamethasone-Induced Hiccups in Chemotherapy May be Prevented by Rotating to Methylprednisolone
- New Evidence Shows Metastases May Spread Independently of Lymph Nodes
- Long Term Survivors of Prostate Cancer Express Treatment Decision Regret for Up to 15 Years
- FDA Expands Clearance for Cooling Cap Use With Chemotherapy for Solid Tumors
- Recommendations for Vaccine Administration During Chemotherapy
- Risk for Prostate Cancer Not Associated With Vasectomy, Meta-analysis Affirms
- Disease-Free Survival After Breast Cancer Comparable With Exemestane, Sequential Tamoxifen/Exemestane
- Treating the Other "Patient": Depressive Symptoms Are Predictive of Declining Physical Health in Caregivers
- Oropharyngeal Mucositis Pain Effectively Relieved With Indomethacin Oral Spray
- Opioids Overprescribed in Patients Undergoing Surgery
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|